Poxel Outlines Draft Recovery Plan and Calls for Shareholder Meeting

Poxel SA is finalizing a recovery plan aimed at securing the company’s future. The key focus is on prolonging business efforts for Imeglimine, PXL770, and PXL065, ensuring long-term viability through new financing, and resolving existing liabilities. Cost reduction and securing new financing are central strategies, developed with IPF Partners’ support.

An Annual General Meeting is scheduled for December 11, 2025, where shareholders will vote on crucial financial measures. These include a capital increase with preferential subscription rights and a capital increase by offsetting debt, both backed by IPF Partners. Shareholders will also consider the issuance of share warrants.

The success of this plan depends on shareholder approval and no alternative financing options are currently available, putting the company at risk of judicial liquidation if the plan fails.